Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) Invested Capital (2016 - 2025)

Historic Invested Capital for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $1.3 million.

  • NovaBay Pharmaceuticals' Invested Capital rose 1202.14% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 1202.14%. This contributed to the annual value of -$64000.0 for FY2024, which is 10124.39% down from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Invested Capital of $1.3 million as of Q3 2025, which was up 1202.14% from $4.4 million recorded in Q2 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' Invested Capital peaked at $17.7 million during Q1 2022, and registered a low of -$64000.0 during Q4 2024.
  • Moreover, its 5-year median value for Invested Capital was $8.9 million (2023), whereas its average is $7.7 million.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Invested Capital tumbled by 10124.39% in 2024 and then surged by 290413.79% in 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' Invested Capital (Quarter) stood at $10.3 million in 2021, then rose by 2.71% to $10.6 million in 2022, then tumbled by 51.25% to $5.1 million in 2023, then plummeted by 101.24% to -$64000.0 in 2024, then soared by 2065.62% to $1.3 million in 2025.
  • Its Invested Capital stands at $1.3 million for Q3 2025, versus $4.4 million for Q2 2025 and $6.3 million for Q1 2025.